ARTÍCULO

Absence of contribution to a differential outcome of the stringent complete response IMWG category respect to the conventional CR in multiple myeloma. a validation analysis based on the pethema/GEM2012MENOS65 phase III clinical trial

Autores: Jiménez-Ubieto, A.; Martinez-Lopez, J.; Rosinol, L. ; Lourenco Paiva, Bruno David; Cedena, M. T.; Puig, N. ; Calasanz Abinzano, María José; Gonzalez-Medina, J.; Martin-Ramos, M. L. ; Alonso-Fernandez, R.; Oriol, A.; Blanchard, J.; Ocio, E. M.; De La Rubia, J. ; Rios, R. ; Martin, J.; Hernandez, M. T.; Krsnik, I.; Moraleda, J. M.; Palomera, L.; Bargay, J.; Mateos, M. V. ; San Miguel Izquierdo, Jesús Fernando; Blade, J.; Lahuerta, J. J.
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 132
Número: Suppl 1
Páginas: 1943
Fecha de publicación: 2018
Lugar: WOS
Resumen:
Introduction: To discriminate different outcomes among patients in CR, the International Myeloma Working Group (IMWG )introduced more stringent CR (sCR) criteria by adding to the pre-existing CR parameters the requirement of a normal free-light chain ratio (sFLCr) plus the absence of clonal plasma cells (PCs) in bone marrow (BM) by immunohistochemistry (IHC). In 2011,the low-sensitivity cytometrycriteria were included as alternative methodology to IHC to define sCR. Aim: To validate the preliminary data of our previous study (Blood 2015. 126:858-62) regarding the lack of influence of an abnormal sFLCr in the outcome of MM patients, through the analysis of a more extensiveseries of newly diagnosed multiple myeloma (NDMM) patients in CR or sCR. Patients and Methods: This study is based on 459 NDMM patients who were transplant candidates and enrolled in the GEM2012MENOS65phase 3trial;evaluable patients were enrolled in a subsequent maintenance trial (NCT02406144).CR and sCR was defined according to the IMWG criteria.